Skip to main content
Premium Trial:

Request an Annual Quote

Swiss Proteomics Firm Biognosys Raises $3M in Series A

NEW YORK (GenomeWeb News) – Swiss proteomics firm Biognosys has raised CHF2.7 million ($3 million) in a Series A round, it announced on Monday.

Participants in the round include Hellmut Kirchner, the co-founder of venture fund Techno Venture Management; Redalpine Capital I, which led Biognosys' seed funding in 2009; ZKB, the venture arm of Cantonal Bank of Zurich; Syngenta Ventures; and private investors.

"With the completion of this Series A round, we are well capitalized to bring Biognosys to the next phase of growth," Oliver Rinner, the company's CEO, said in a statement. He did not provide further details about the use of the funds.

In connection with the funding, Biognosys also announced additions to its board including Kirchner, Ignacio Martinez, a principal in Syngenta Ventures, and Harry Welten, CFO of Cytos Biotechnology.

Biognosys was spun out of the Swiss Federal Institute of Technology in 2008 and provides targeted mass spectrometry-based services to companies operating in the diagnostics, pharma, healthcare, biotechnology, and agricultural spaces. Customers include Novartis, Pfizer, Integrated Diagnostics, and Philips, according to its website.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.